Driven by Purpose: Advancing Therapeutics for a Healthier Future
At Delica Therapeutics, we are driven by a vision to push the boundaries of science and nature to create impactful solutions for health and wellness. Our projects focus on unlocking the full potential of psychedelics, flavonoids, and new-to-nature chemical entities—each offering opportunities to address some of the world’s most pressing mental health challenges. We are committed to advancing research and developing sustainable, innovative compounds that pave the way for the future of therapeutic solutions.
Project 1 | Psilocybin for mental health
The Problem:
Mental health remains a substantial global challenge, with treatment options having limited impact on the majority of those suffering from mental illness.
The Solution:
As research accelerates, psilocybin is emerging as a promising solution for treatment-resistant depression. Doctors and scientists are increasingly exploring its potential, with over 150 clinical trials underway in the US alone.
Regulatory shifts reflect this momentum. The US Drug Enforcement Agency has continued to increase the psilocybin production quota year-on-year., As interest in this powerful medicinecontinues to grow, sustainable and scalable manufacturing solutions are essential.
At Delica Therapeutics, we are working to bridge this gap by developing innovative production methods, ensuring a consistent, high-quality supply to support the future of psychedelic-assisted therapies.
Project 2 | Cannflavins for inflammation
The Problem:
Despite their widespread use, traditional anti-inflammatory drugs like non-steroidal anti-inflammatories (NSAIDs)come with limitations, including potential side effects and limited efficacy for chronic conditions. While nature holds powerful alternatives, compounds like Cannflavins A and B are incredibly rare and difficult to source at scale. Without advanced manufacturing, their full potential remains untapped—leaving a gap in the search for safer, more effective anti-inflammatory solutions.
The Solution:
Cannflavins A and B are rare, naturally occurring compounds with remarkable anti-inflammatory and neuroprotective properties. Studies suggest they are 30 times more powerful than traditional NSAIDs like aspirin, offering a promising alternative for managing inflammation without the side effects associated with conventional treatments.
At Delica Therapeutics, we are harnessing advanced manufacturing to unlock the full potential of Cannflavins—paving the way for next-generation therapeutics in inflammation and neuroprotection.
Project 3 | New Chemical Entity (DT001)
During the development of a production system for Cannflavins A and B, a new compound—DT001—was discovered. DT001 is hypothesised to be a more potent antioxidant, offering exciting potential for therapeutic applications.
The opportunity:
DT001 presents exciting therapeutic potential across the same areas as Cannflavins A and B, with a chemical structure predicted to enhance its mechanism of action—potentially increasing its therapeutic value. While research on Cannflavins has been largely limited to pre-clinical validation due to supply constraints, the advanced production system developed for DT001 overcomes these challenges, enabling meaningful drug quantities for further research and development.
Send us a message
If you are interested in working with our compounds or have any questions, please reach out to discuss how Delica can help.